natgillin/translations-raw huggingface dataset:
Plasma protein binding was low, approximately 40%.
Vezava na beljakovine plazme je nizka, le okoli 40%.
For any respiratory disease, it is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment within 48 hours after injection.
Pri vseh respiratornih boleznih se priporoča zdravljenje živali v zgodnjih fazah bolezni ter preverjanje učinka zdravljenja 48 ur po vbrizgavanju.
Muscle Fat
Mišice Maščoba
Cattle: 22 days.
Govedo: 22 dni.
Sheep: 16 days.
Ovce: 16 dni.
No such reactions have been observed in pigs and sheep after intramuscular administration.
Teh reakcij pri prašičih in ovca po intramuskularnem dajanju ni bilo opaziti.
In both bovine and porcine polymorphonuclear cells (PMNs; neutrophils), tulathromycin promotes apoptosis (programmed cell death) and the clearance of apoptotic cells by macrophages.
Pri obeh, govejih in prašičjih polimorfonuklearnih celicah (PMN; neutrofilci), tulatromicin spodbuja apoptozo (programirana celična smrt) in očiščenje apoptotskih celic z makrofagi.
Date of first authorisation: 11/11/2003.
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 11.11.2003.
Draxxin showed limited efficacy in sheep with severe clinical signs or chronic foot rot, and should therefore only be given at an early stage of foot rot.
Draxxin je kazal omejeno učinkovitost pri ovcah s hudimi kliničnimi znaki ali pri kronični obliki nalezljive šepavosti ovac, zato ga dajemo le v zgodnjih fazah bolezni.
Monothioglycerol Propylene glycol Citric acid Hydrochloric acid Sodium hydroxide Water for injections
Seznam pomožnih snovi monotioglicerol propilenglikol citronska kislina klorovodikova kislina natrijev hidroksid voda za injekcije
In case of accidental eye exposure, flush the eyes immediately with clean water.
V primeru nenamernega stika očesa z zdravilom, prizadeto oko nemudoma sprati s čisto vodo.
Official, national and regional antimicrobial policies should be taken into account when the product is used.
Uporaba zdravila naj bo v skladu z uradnimi, nacionalnimi in regionalnimi doktrinami protimikrobnega zdravljenja.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/).
Evropske agencije za zdravila http://www.ema.europa.eu/
Pharmacotherapeutic group: Antibacterials for systemic use, macrolides.
Farmakoterapevtska skupina: Zdravila za sistemsko zdravljenje bakterijskih infekcij, makrolidi.
To ensure correct dosage bodyweight should be determined as accurately as possible to avoid underdosing.
Za zagotovitev pravilnega odmerjanja je potrebno čim natančneje določiti telesno maso obolele živali, da zagotovimo zadostno odmerjanje zdravila.
Resistance to macrolides can develop by mutations in genes encoding ribosomal RNA (rRNA) or some ribosomal proteins; by enzymatic modification (methylation) of the 23S rRNA target site, generally giving rise to cross-resistance with lincosamides and group B streptogramins (MLSB resistance); by enzymatic inactivation; or by macrolide efflux.
Rezistenca na makrolide se lahko razvije zaradi mutacij genov, ki kodirajo ribosomalno RNK (rRNK) oziroma nekaterih ribosomalnih proteinov; z encimsko modifikacijo (metilacijo) 23S rRNK tarčnega mesta, kar običajno povzroči povečanje navzkrižne rezistence z likozamidi in skupino B streptogramnov (MLSB rezistenca); z encimsko inaktivacijo ali pa z izločanjem makrolidov.
DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION
ODMEREK ZA POSAMEZNE ŽIVALSKE VRSTE TER POT(I) IN NAČIN UPORABE ZDRAVILA
In addition to its antimicrobial properties, tulathromycin demonstrates immune-modulating and antiinflammatory actions in experimental studies.
Tulatromicin poleg protimikrobnih lastnosti, dokazuje tudi imunomodulacijsko in protivnetno delovanje v poskusnih študijah.
Macrolides are bacteriostatic acting antibiotics and inhibit essential protein biosynthesis by virtue of their selective binding to bacterial ribosomal RNA.
Makrolidi so antibiotiki z bakteriostatičnim načinom delovanja, ki zavirajo sintezo nujno potrebnih proteinov s selektivno vezavo na bakterijsko ribosomalno RNK.
Tulathromycin
tulatromicin
Treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent Dichelobacter nodosus requiring systemic treatment.
Zdravljenje zgodnjih faz nalezljive šepavosti ovac (foot rot) v povezavi z virulentno bakterijo Dichelobacter nodosus, ki zahteva sistemsko zdravljenje.
Antiinfectious agents/ Antibiotics'
/Antibiotik
Vall de Bianya 17813 (Gerona) SPAIN
Vall de Bianya 17813 (Girona) SPAIN
5 mg/ml For the full list of excipients, see section 6.1.
Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
500 ml vials must not be used for pigs and sheep.
500 ml viale se ne smejo uporabljati za zdravljenje prašičev in ovca.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER IMETNIKA DOVOLJENJA ZA PROIZVODNJO ZDRAVILA, ODGOVORNEGA ZA SPROŠČANJE SERIJ V EGP, ČE STA RAZLIČNA
For multiple vial entry, an aspirating needle or multi-dose syringe is recommended to avoid excessive broaching of the stopper.
V kolikor zdravimo več živali se priporoča uporaba aspiracijske igle ali pa brizge za večkratno odmerjanje, da se izognemo večkratnemu prebadanju zamaška.
14R)-2-ethyl tetrahydroxy hexamethyl trideoxy-3(dimethylamin o)-ß-Dxylohexopyranosyl]oxy]-1oxa-6azacyclopentde-can-15-one expressed as tulathromycin equivalents
14R)-2-ethyl tetrahydroxy hexamethyl trideoxy-3(dimethylamin o)-ß-D
Subcutaneous administration of Draxxin to cattle causes very commonly transient pain reactions and local swellings at the injection site that can persist for up to 30 days.
Pri govedu podkožno vbrizgavanje Draxxina pogosto povzroči trenutno bolečino in lokalno oteklino na mestu vbrizgavanja, ki lahko vztraja tudi do 30 dni.
Treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis sensitive to tulathromycin.
Zdravljenje infekcioznega govejega keratokonjuktivitisa (IBK), povzročenega z Moraxella bovis občutljivo na tulatromicin.
Interaction with other medicinal products and other forms of interaction: Do not administer simultaneously with antimicrobials with a similar mode of action such as other macrolides or lincosamides.
Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Ne uporabljajte hkrati z drugimi antimikrobnimi sredstvi, ki imajo podoben način delovanja, kot so drugi makrolidi in linkozamidi.
MARKETING AUTHORISATION
IMETNIK DOVOLJENJA ZA PROMET
Vial sizes: 50, 100 and 250 ml.
Velikost vial: 50, 100 in 250 ml.
Primary packaging: Type I glass vial with a fluoropolymer coated chlorobutyl stopper and an aluminium overseal.
Stična ovojnina: steklena viala tipa 1 s klorobutilnim zamaškom prevlečenim s fluoropolimerom in aluminijasto zaporko.
Do not administer simultaneously with antimicrobials with a similar mode of action such as other macrolides or lincosamides.
Ne uporabljajte hkrati z drugimi antimikrobnimi sredstvi, ki imajo podoben način delovanja, kot so drugi makrolidi in linkozamidi.
Tulathromycin is a semi-synthetic macrolide antimicrobial agent, which originates from a fermentation product.
Tulatromicin je polsintetično protimikrobno zdravilo iz skupine makrolidov, ki izvira iz produktov fermentacije.
In case of accidental spillage onto skin, wash the skin immediately with soap and water.
Pri nenamernem stiku kože z zdravilom, je potrebno kožo nemudoma sprati z milom in vodo.
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. STATEMENT OF THE MRLs
DODATEK II A. IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL) D. DRUGI POGOJI IN ZAHTEVE KI JIH MORA IZPOLNITI IMETNIK DOVOLJENJA ZA PROMET Z ZDRAVILOM
In sheep, the pharmacokinetic profile of tulathromycin, when administered as a single intramuscular dose of 2.5 mg/kg bodyweight, achieved a maximum plasma concentration (Cmax) of 1.19 µg/ml in approximately 15 minutes (Tmax) post-dosing and had an elimination half-life (t1/2) of 69.7 hours.
Pri ovcah farmakokinetični profil tulatromicina, danega z enkratnim intramuskularnim odmerkom po 2,5 mg/kg telesne mase, doseže najvišjo koncentracijo (Cmax) v plazmi okoli 1,19 μg/ml, dosežena pa je približno 15 minutah po vnosu (Tmax) in ima polovični čas izločitve (T½) 69,7 ur.
4.2 Indications for use, specifying the target species
4.2 Indikacije za uporabo pri ciljnih živalskih vrstah Govedo
4.8 Interaction with other medicinal products and other forms of interaction
4.8 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Lahko se pojavi navzkrižna rezistenca z drugimi makrolidi.
The presence of the disease in the herd should be established before metaphylactic treatment.
Pred metafilaktično uporabo je potrebno dokazati prisotnost bolezni v čredi.
Antibiotic treatment of benign foot rot is not considered appropriate.
Antibiotično zdravljenje benigne oblike nalezljive šepavosti ovac ni primerno.
The maximum concentration (Cmax) in plasma was approximately 0.6 µg/ml; this was achieved approximately 30 minutes post-dosing (Tmax).
Najvišji koncentracija (Cmax) v plazmi je okoli 0,6 μg/ml, dosežena pa je približno 30 minut po vnosu (Tmax).
Peak concentrations were followed by a slow decline in systemic exposure with an apparent elimination half-life (t1/2) of approximately 91 hours in plasma.
Koncentracijskemu vrhu je sledilo počasno pojemanje sistemskih učinkov z navideznim polovičnim časom izločitve (T½) okoli 91 ur v plazmi.
Tulathromycin also possesses in vitro activity against Moraxella bovis, the bacterial pathogen most commonly associated with infectious bovine keratoconjunctivitis (IBK).
Tulatromicin izkazuje tudi in vitro aktivnost proti Moraxella bovis patogeni bakteriji, ki je najpogostejša povzročiteljica infekcioznega govejega keratokonjuktivitisa.
It differs from many other macrolides in that it has a long duration of action that is, in part, due to its three amine groups; therefore it has been given the chemical subclass designation of triamilide.
Za razliko od drugih makrolidov ima tulatromicin podaljšano delovanje, ki je posledica treh amino skupin; ravno zaradi njih uvrščamo tulatromicin v kemično podskupino triamilidov.
The maximum concentration (Cmax) in plasma was approximately 0.5 µg/ml; this was achieved approximately 30 minutes post-dosing (Tmax).
Najvišja koncentracija (Cmax) v plazmi je okoli 0,5 μg/ml, dosežena pa je približno 30 minut po vnosu (Tmax).
Name and address of the manufacturers responsible for batch release
Ime in naslov izdelovalca zdravila, odgovornega za sprostitev serije
In pigs, the pharmacokinetic profile of tulathromycin when administered as a single intramuscular dose of 2.5 mg/kg bodyweight, was also characterised by rapid and extensive absorption followed by high distribution and slow elimination.
Pri prašičih je za farmakokinetični profil tulatromicina, vnešenega z enkratnim intramuskularnim vbrizgom v dozi 2,5 mg/ml, prav tako značilna hitra in obsežna absorpcija, ki ji sledi hitra razporeditev in počasno izločanje.
In cattle, the pharmacokinetic profile of tulathromycin when administered as a single subcutaneous dose of 2.5 mg/kg bodyweight, was characterised by rapid and extensive absorption followed by high distribution and slow elimination.
Pri govedu je za farmakokinetični profil tulatromicina, vnešenega z enkratnim podkožnim vbrizgavanjem v dozi 2,5 mg/ml, značilna hitra in obsežna absorpcija, ki ji sledi hitra razporeditev in počasno izločanje.
Bovine 300 µg/kg 200 µg/kg
Govedo 300 µg/kg
Peak concentrations were followed by a slow decline in systemic exposure with an apparent elimination half-life (t1/2) of 90 hours in plasma.
Koncentracijskemu vrhu je sledilo počasno pojemanje sistemskih učinkov z navideznim polovičnim časom izločitve (T½) okoli 90 ur v plazmi.
Vial sizes: 20 ml, 50 ml, 100 ml, 250 ml and 500 ml.
Velikost vial: 20 ml, 50 ml, 100 ml 250 ml in 500 ml.
The bioavailability of tulathromycin after intramuscular administration in sheep was 100%.
Biorazpoložljivost tulatromicina po intramuskularnem vnosu pri ovcah je 100%.
Cattle: SC. Pigs and sheep: IM.
Prašiči in ovce: i.m.
Treatment of foot rot should therefore be undertaken along with other flock management tools, for example providing dry environment.
Za zdravljenje nalezljive šepavosti ovac je potrebno upoštevati vsa merila dobrega upravljanja s čredo, kot naprimer zagotavljanje suhega okolja.
Draxxin 25 mg/ml: Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM
Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIJA
Draxxin 100 mg/ml: FAREVA AMBOISE Zone Industrielle, 29 route des Industries 37530 Pocé-sur-Cisse FRANCE
FAREVA AMBOISE Zone Industrielle, 29 route des Industries
For treatment of cattle over 300 kg bodyweight, divide the dose so that no more than 7.5 ml are injected at one site.
Za goveda s telesno maso nad 300 kg, je potrebno odmerek razdeliti tako, da na eno mesto injiciranja ne vbrizgamo več kot 7,5 ml zdravila.
Pigs (meat and offal): 13 days.
Prašiči (meso in organi): 13 dni.
Cattle: For subcutaneous use.
NAČIN IN POT(I) UPORABE Govedo: za subkutano uporabo.
The bioavailability of tulathromycin after subcutaneous administration in cattle was approximately 90%.
Biorazpoložljivost tulatromicina po podkožnem vnosu pri govedu je približno 90%.
In sheep, transient signs of discomfort (head shaking, rubbing injection site, backing away) are very common after intramuscular injection.
Pri ovcah so prehodni znaki neugodja (stresanje glave, drgnjenje mesta injiciranja, umikanje) so zelo pogosti po intramuskularnem injiciranju.
Sheep (meat and offal): 16 days.
Ovce (meso in organi): 16 dni.
4500 µg/kg 3000 µg/kg
4500 μg/kg 3000 μg/kg
SPECIAL WARNING(S), IF NECESSARY
POSEBNO(A) OPOZORIL(O)A
INDICATIONS Cattle
INDIKACIJA(E) Govedo
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box (20 ml / 50 ml / 100 ml / 250 ml)
PODATKI NA ZUNANJI OVOJNINI Kartonska škatla (20 ml / 50 ml / 100 ml / 250 ml)
The bioavailability of tulathromycin after intramuscular administration in pigs was approximately 88%.
Biološka uporabnost tulatromicina po podkožnem vnosu pri prašičih je približno 88%.
Do not use in pregnant animals, which are intended to produce milk for human consumption, within 2 months of expected parturition.
Ne uporabite pri brejih živalih, katerih mleko je namenjeno prehrani ljudi, v obdobju 2 mesecev pred pričakovanim porodom.
In sheep transient signs of discomfort (head shaking, rubbing injection site, backing away) are very common after intramuscular injection.
Prehodni znaki neugodja (stresanje glave, drgnjenje mesta injiciranja, umikanje) so zelo pogosti po intramuskularnem injiciranju.
In young pigs weighing approximately 10 kg given three or five times the therapeutic dose transient signs attributed to injection site discomfort were observed and included excessive vocalisation and restlessness.
Pri mladih prašičih s telesno maso okoli 10 kg, ki so prejeli trikraten oziroma petkraten terapevtski odmerek, so bili opaženi prehodni znaki, vezani predvsem na moteč občutek na mestu vbrizgavanja, glasno oglašanje in nemir.
Pathomorphological injection site reactions (including reversible changes of congestion, oedema, fibrosis and haemorrhage) are present for approximately 30 days after injection.
Patomorfološke reakcije na mestu injiciranja (vključno z reverzibilnimi spremembami kongestije, edem, fibroza in krvavitve) so prisotne približno 30 dni po injiciranju.
Pathomorphological injection site reactions (including reversible changes of congestion, oedema, fibrosis and haemorrhage) are very common for approximately 30 days after injection in cattle and pigs.
Patomorfološke reakcije na mestu injiciranja (vključno z reverzibilnimi spremembami kongestije, edemom, fibrozo in krvavitvami) so zelo pogoste, še približno 30 dni po injiciranju pri govedu in prašičih.
Do not use simultaneously with other macrolides or lincosamides (see section 4.8).
Ne uporabite zdravila skupaj z drugimi makrolidnimi antibiotiki ali linkozamidi (glej poglavje 4.8) 4.4 Posebna opozorila za vsako ciljno živalsko vrsto Jih ni.
Increased minimum inhibitory concentration (MIC) values have been found in some isolates of Histophilus somni and Actinobacillus pleuropneumoniae.
Pri nekaterih izolatih Histophilus somni in Actinobacyllus pleuropneumoniae so bile ugotovljene povišane vrednosti minimalne inhibitorne koncentracije (MIC).
Do not use simultaneously with other macrolides or lincosamides.
Ne uporabite zdravila skupaj z drugimi makrolidnimi antibiotiki ali linkozamidi.
Mild myocardial degeneration has been observed in cattle receiving 5 to 6 times the recommended dose.
Pri govedu, ki je dobilo 5-6 kratni odmerek, je bila opažena rahla degeneracija miokarda.
In vitro activity against Dichelobacter nodosus (vir), the bacterial pathogen most commonly associated with infectious pododermatitis (foot rot) in sheep has been demonstrated.
Dokazano je bilo In vitro delovanje proti bakteriji Dichelobacter nodosus (vir), pathogenu, ki je najpogosteje povezan z nalezljivo šepavostjo ovac.
Tulathromycin concentrations in lung homogenate were considerably higher than those in plasma.
V homogenizatu pljučnega tkiva je bil zaznan tulatromicin v bistveno višji koncentraciji kot v plazmi, kar očitno kaže na njegovo obilno kopičenje v nevtrofilcih in alveolarnih makrofagih.
Cattle (meat and offal): 22 days.
Govedo (meso in organi): 22 dni.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
Posebni previdnostni ukrepi, ki jih mora izvajati oseba, ki živalim daje zdravilo Tulatromicin draži očesno sluznico.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box (50 ml / 100 ml / 250 ml)
PODATKI NA ZUNANJI OVOJNINI Kartonska škatla (50 ml / 100 ml / 250 ml)
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box (500 ml)
PODATKI NA ZUNANJI OVOJNINI Kartonska škatla (500 ml)
Meat and offal: 13 days.
Meso in organi:13 dni.
Tulathromycin possesses in vitro activity against Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis and Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica the bacterial pathogens most commonly associated with bovine and swine respiratory disease, respectively.
Tulatromicin izkazuje in vitro aktivnost proti Mannheimia haemolytica, Pasteurella multocida, Histophilus somni in Mycoplasma bovis ter proti Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis in Bordetella bronchiseptica to je proti patogenim bakterijam, ki so najpogostejši povzročitelji obolenj dihal pri govedu in prašičih.
Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis sensitive to tulathromycin.
Zdravljenje in metafilaksa dihalnih obolenj goveda (BRD), povzročenih z Mannheimia haemolytica, Pasteurella multocida, Histophilus somni in Mycoplasma bovis občutljivih na tulatromicin.
For treatment of pigs over 40 kg bodyweight, divide the dose so that no more than 4 ml are injected at one site.
Pri zdravljenju prašičev, ki so težji od 40 kg, je potrebno odmerek razdeliti tako, da na eno mesto injiciranja ne vbrizgamo več kot 4 ml zdravila.
For treatment of pigs over 80 kg bodyweight, divide the dose so that no more than 2 ml are injected at one site.
Pri zdravljenju prašičev, ki so težji od 80 kg, je potrebno odmerek razdeliti tako, da na eno mesto injiciranja ne vbrizgamo več kot 2 ml zdravila.
Porcine 800 µg/kg 300 µg/kg
800 µg/kg 300 μg/kg
Do not use in lactating animals producing milk for human consumption.
Ne uporabite zdravila pri živalih, namenjenih za proizvodnjo mleka za prehrano ljudi.
Lameness was also observed when the hind leg was used as the injection site.
V primeru vbrizgavanja v zadnjo nogo so bili opaženi tudi znaki ohromelosti.
EXP Shelf life after first opening the container: 28 days.
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini po EXP. Rok uporabnosti po prvem odpiranju vsebnika: 28 dni.
Draxxin 100 mg/ml solution for injection for cattle tulathromycin
Draxxin 100 mg/ml raztopina za injiciranje za govedo tulatromicin
Liver Kidney
Jetra Ledvice
Draxxin 25 mg/ml solution for injection for pigs tulathromycin
Draxxin 25 mg/ml raztopina za injiciranje za prašiče tulatromicin
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Vial (500 ml)
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA STIČNIH OVOJNINAH Viala (500 ml)
Draxxin 25 mg/ml solution for injection for pigs
Draxxin 25 mg/ml raztopina za injiciranje za prašiče
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Vial (100 ml / 250 ml)
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA STIČNIH OVOJNINAH Viala (100 ml / 250 ml)
EXP Once broached use by
EXP Načeto zdravilo uporabite do…
In cattle at dosages of three, five or ten times the recommended dose, transient signs attributed to injection site discomfort were observed and included restlessness, head-shaking, pawing the ground, and brief decrease in feed intake.
Pri govedu so bili pri vbrizgavanju trikratne, petkratne in desetkratne priporočene doze opaženi prehodni znaki, vezani predvsem na moteč občutek na mestu vbrizgavanja.
Marker residue Animal species
Marker ostanek
Draxxin 100 mg/ml solution for injection for cattle, pigs and sheep Tulathromycin
Draxxin 100 mg/ml raztopina za injiciranje za goveda, prašiče in ovce tulatromicin
PACKAGE LEAFLET: Draxxin 25 mg/ml solution for injection for pigs
NAVODILO ZA UPORABO Draxxin 25 mg/ml raztopina za injiciranje za prašiče
Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica sensitive to tulathromycin.
Zdravljenje in metafilaksa dihalnih obolenj prašičev (SRD), povzročenih z Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae,Haemophilus parasuis in
Draxxin 100 mg/ml solution for injection for cattle, pigs and sheep
Draxxin 100 mg/ml raztopina za injiciranje za govedo, prašiče in ovce
Not for use in animals from which milk is produced for human consumption.
Ni za uporabo pri živalih v laktaciji, katerih mleko je namejeno za prehrano ljudi.
PACKAGE LEAFLET: Draxxin 100 mg/ml solution for injection for cattle, pigs and sheep
NAVODILO ZA UPORABO Draxxin 100 mg/ml raztopina za injiciranje za govedo, prašiče in ovce
A single intramuscular injection of 2.5 mg tulathromycin/kg body weight (equivalent to 1 ml/40 kg body weight) in the neck.
Enkratna intramuskularna injekcija tulatromicina v odmerku 2,5 mg/kg telesne mase (kar ustreza 1 ml na 40 kg telesne mase) v področje vratu.
A single subcutaneous injection of 2.5 mg tulathromycin/kg bodyweight (equivalent to 1 ml/40 kg bodyweight).
Enkratno podkožno dajanje tulatromicina v odmerku 2,5 mg/kg telesne mase (kar ustreza 1 ml na 40
The volume of distribution at steady-state (VSS) determined after intravenous administration was 11 l/kg.
Volumen distribucije v fazi stabilizacije koncentracije (VSS), določen po intravenoznem vnosu je 11 L/kg.
The volume of distribution at steady-state (Vss) determined after intravenous administration was 11 l/kg.
Volumen distribucije v fazi stabilizacije koncentracije (VSS), določen po intravenoznem vnosu je 11 l/kg.
In lambs (approx. 6 weeks old), at dosages of three or five times the recommended dose, transient signs attributed to injection site discomfort were observed, and included walking backwards, head shaking, rubbing the injection site, lying down and getting up, bleating.
Pri jagnjetih (približno 6 tednov starih), ki so prejeli trikraten oziroma petkraten priporočeni odmerek,so bili opaženi prehodni znaki, vezani predvsem na moteč občutek na mestu injiciranja,